Literature DB >> 7509807

Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor.

M A Cascieri1, A M Macleod, D Underwood, L L Shiao, E Ber, S Sadowski, H Yu, K J Merchant, C J Swain, C D Strader.   

Abstract

We have recently shown that a series of N-acyl-L-tryptophan benzyl esters are potent substance P antagonists (Macleod, A. M., Merchant, K. J., Cascieri, M. A., Sadowski, S., Ber, E., Swain, C. J., and Baker, R. (1993) J. Med Chem. 14, 2044-2045). We now report the detailed characterization of the interaction of N-acetyl-L-tryptophan-3,5-bistrifluoromethyl benzyl ester (L-732,138) with the human neurokinin-1 (NK-1) receptor. L-732,138 inhibits the binding of 125I-substance P to the cloned human NK1 receptor expressed in Chinese hamster ovary cells with an IC50 of 2.3 +/- 0.7 nM. In contrast, it has 200-fold lower affinity for the cloned rat NK-1 receptor and has > 1000-fold lower affinity for the human NK-2 and NK-3 receptors. L-732,138 acts as a competitive antagonist of substance P, as shown by functional Schild analysis of the inhibition of substance P-induced inositol phosphate synthesis, by kinetic analysis of the dissociation rate, and by thermodynamic analysis of the equilibrium binding of 125I-substance P to the NK-1 receptor. L-732,138 also competitively inhibits the binding of the quinuclidine amine antagonist, [125I]L-703,606, to the receptor. The compound has 230- and 10-fold reduced affinity for mutant NK-1 receptors in which histidine 265 or histidine 197, respectively, are replaced with alanine. We have previously shown that these residues play key roles in the binding of quinuclidine antagonists to the NK-1 receptor. These results suggest that the tryptophan and quinuclidine series of NK-1 antagonists bind to similar binding sites on the human NK-1 receptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509807

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Pharmacophore and receptor models for neurokinin receptors.

Authors:  Anders Poulsen; Berith Bjørnholm; Klaus Gundertofte; Irina D Pogozheva; Tommy Liljefors
Journal:  J Comput Aided Mol Des       Date:  2003-11       Impact factor: 3.686

2.  Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.

Authors:  Steven Ballet; Debby Feytens; Koen Buysse; Nga N Chung; Carole Lemieux; Suneeta Tumati; Attila Keresztes; Joost Van Duppen; Josephine Lai; Eva Varga; Frank Porreca; Peter W Schiller; Jozef Vanden Broeck; Dirk Tourwé
Journal:  J Med Chem       Date:  2011-03-17       Impact factor: 7.446

3.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.

Authors:  Takashi Yamamoto; Padma Nair; Tally M Largent-Milnes; Neil E Jacobsen; Peg Davis; Shou-Wu Ma; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  J Med Chem       Date:  2011-03-02       Impact factor: 7.446

4.  Development of a spontaneously active dorsal root ganglia assay using multiwell multielectrode arrays.

Authors:  Kim Newberry; Shuya Wang; Nina Hoque; Laszlo Kiss; Michael K Ahlijanian; James Herrington; John D Graef
Journal:  J Neurophysiol       Date:  2016-04-06       Impact factor: 2.714

Review 5.  Involvement of substance P and the NK-1 receptor in pancreatic cancer.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

6.  Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor.

Authors:  K Prendergast; K Adams; W J Greenlee; R B Nachbar; A A Patchett; D J Underwood
Journal:  J Comput Aided Mol Des       Date:  1994-10       Impact factor: 3.686

Review 7.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

8.  The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Neil E Jacobsen; Peg Davis; Shou-wu Ma; Edita Navratilova; Sharif Moye; Josephine Lai; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2008-09-27       Impact factor: 7.446

9.  The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety.

Authors:  Takashi Yamamoto; Padma Nair; Shou-wu Ma; Peg Davis; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2009-08-21       Impact factor: 3.641

10.  Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Authors:  Padma Nair; Takashi Yamamoto; Scott Cowell; Vinod Kulkarni; Sharif Moye; Edita Navratilova; Peg Davis; Shou-Wu Ma; Todd W Vanderah; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2015-06-15       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.